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Abstract
Background: In sub-Saharan Africa antiretroviral therapy (ART) is being decentralized from tertiary/secondary care
facilities to primary care. The Lablite project supports effective decentralization in 3 countries. It began with a
cross-sectional survey to describe HIV and ART services.
Methods: 81 purposively sampled health facilities in Malawi, Uganda and Zimbabwe were surveyed.
Results: The lowest level primary health centres comprised 16/20, 21/39 and 16/22 facilities included in Malawi,
Uganda and Zimbabwe respectively. In Malawi and Uganda most primary health facilities had at least 1 medical
assistant/clinical officer, with average 2.5 and 4 nurses/midwives for median catchment populations of 29,275 and
9,000 respectively. Primary health facilities in Zimbabwe were run by nurses/midwives, with average 6 for a median
catchment population of 8,616. All primary health facilities provided HIV testing and counselling, 50/53 (94%)
cotrimoxazole preventive therapy (CPT), 52/53 (98%) prevention of mother-to-child transmission of HIV (PMTCT) and
30/53 (57%) ART management (1/30 post ART-initiation follow-up only). All secondary and tertiary-level facilities
provided HIV and ART services. In total, 58/81 had ART provision. Stock-outs during the 3 months prior to survey
occurred across facility levels for HIV test-kits in 55%, 26% and 9% facilities in Malawi, Uganda and Zimbabwe
respectively; for CPT in 58%, 32% and 9% and for PMTCT drugs in 26%, 10% and 0% of facilities (excluding facilities
where patients were referred out for either drug). Across all countries, in facilities with ART stored on-site, adult ART
stock-outs were reported in 3/44 (7%) facilities compared with 10/43 (23%) facility stock-outs of paediatric ART.
Laboratory services at primary health facilities were limited: CD4 was used for ART initiation in 4/9, 5/6 and 13/14 in
Malawi, Uganda and Zimbabwe respectively, but frequently only in selected patients. Routine viral load monitoring
was not used; 6/58 (10%) facilities with ART provision accessed centralised viral loads for selected patients.
Conclusions: Although coverage of HIV testing, PMTCT and cotrimoxazole prophylaxis was high in all countries,
decentralization of ART services was variable and incomplete. Challenges of staffing and stock management were
evident. Laboratory testing for toxicity and treatment effectiveness monitoring was not available in most primary
level facilities.
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Background
Most HIV-infected individuals on antiretroviral therapy
(ART) in low and middle-income countries are treated
following the World Health Organization (WHO) public
health approach [1]. The public sector provides one
standard first-line regimen, with alternative drug substi-
tutions for anti-tuberculosis (TB) co-therapy or first-line
regimen toxicity [1]. When first-line failure occurs, the
patient switches to a standard boosted-protease inhibitor
(PI)-based second-line regimen [1]. National guidelines
specify simple ART formularies with few combination
drugs in order to facilitate procurement and supply-chain
management [2-4]. Decentralization (delivery of services
outside specialist centres) and task shifting (delegation of
routine services to lower level relevant cadre) are key
components of equitable public sector roll-out to ensure
access to ART beyond ART facilities in tertiary centres
and those operating in well-supported research programs
[5-13]. Access to HIV testing and ART has been priori-
tized over laboratory services for monitoring ART toxicity
and identifying treatment failure and the need to switch to
second-line [14]. This has enabled large numbers of indi-
viduals to access ART and to remain on therapy [15]. It
will remain the bedrock for further service expansion to-
wards universal ART access, particularly in sub-Saharan
African countries with generalized HIV epidemics, con-
strained health budgets and fragile health systems.
Funding for HIV and AIDS programs is generally static
and has even recently declined in some resource con-
strained countries [16]. The “first-line/second-line” para-
digm and the ensuing simplified formularies are not in
question and decentralization remains a core policy ob-
jective in most countries. Despite robust clinical trials
evidence demonstrating that ART may be given in both
adults and children without routine laboratory monitor-
ing [17-19], there remains an on-going debate about
whether to prioritize limited funding towards laboratory
capacity building for monitoring or expanding access to
treatment [20,21]. The 2013 WHO guidelines [22] pro-
mote both wider access to viral load monitoring and ex-
panded entry into care (through raising the CD4
threshold for ART initiation and the ‘B plus’ approach to
prevention of mother-to-child transmission whereby
pregnant women start ART for life), without specific
guidance on how to prioritize across these different as-
pirational approaches.
As these debates continue, many countries continue to
decentralize their ART programs and policymakers face
the challenge of prioritizing equity in access to ART
with laboratory services and other health systems gaps.
Although there are numerous studies describing decen-
tralized ART programs in sub-Saharan African countries
[5,6,9,10,23-27], few have described the state of national
ART roll-out at the lowest level of decentralized primary
service delivery. Moreover these studies [28,29] have
assessed epidemiologic program outcomes (mortality and
lost to follow-up) but have generally not described HIV
service decentralization through a health systems lens.
There also remains a need to gather evidence on the
safety, efficacy and cost-effectiveness of decentralization of
services as clinically directed monitoring is operationalized
in the context of limited laboratory support, outside of na-
tional centres of excellence.
Malawi, Uganda and Zimbabwe account for about 11%
of people living with HIV globally and national ART
coverage rates from 2012 UNAIDS data were 70%, 64%
and 80% respectively, increased from 67%, 54% and 77%
in 2011 [15]. Public sector scale-up of ART in these
countries began about a decade ago, but decentralization
and ART coverage at the lowest level of health services
remain variable [30]. The Lablite project (www.lablite.
org; 2011–2015) is a multi-country implementation pro-
ject in these three countries to evaluate whether decen-
tralized ART care can be delivered effectively at lower level
health centres with limited laboratory services, and to as-
sess the economic implications of decentralization employ-
ing a low technology, task-shifting strategy. Lablite began
with a cross-sectional survey of representative health facil-
ities to describe and compare national and inter-country
delivery of training, clinical care and use of laboratories and
monitoring in ART roll-out, providing a baseline for the
project; this baseline survey is described here.
Methods
Study setting
Malawi (population 15 million), had a HIV prevalence of
11% among those aged 15–49 in 2012 [15]. ART cover-
age had expanded dramatically from 9 sites in 2003 to
over 550 sites (67 private sector) at the time of initiation
of the baseline study in October 2011, with over 275,000
HIV-positive individuals alive and on treatment [31].
The public health system in Malawi is organized into 3
levels: a) primary: consisting of community initiatives,
health posts, dispensaries, maternity units, health centres
(HC) which provide outpatient, antenatal, maternity,
immunization and outreach services, and a transitional
level of community and rural hospitals which provide in-
patient care; b) secondary: district hospital referral cen-
tres that provide inpatient and outpatient services and
are primarily based in towns; c) tertiary: 4 central hospi-
tals that provide specialist referral health services for
their respective health zones. A mid-level supervisory
structure is organized geographically into 5 zonal health
support offices, which provides support to a cluster of
district health management teams who are responsible
for coordinating the secondary and primary health facil-
ities as well as the referral system within each district.
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Uganda (population 34.5 million) had a prevalence of 7%
among those aged 15–49 in 2012 [15]. It has the most ma-
ture ART program of the three countries, with availability
of medication since 1998 through NGOs, the private sector
and academic institutions. At the time of the baseline sur-
vey, end 2011, 313,000 HIV positive-individuals were on
ART [32]. Provision was as per the 2009 national ART
guidelines [3]. Health facilities are categorized according to
the area served and services provided as: a) Health Centre
II (HC II) which serves a parish with population ~5,000
and provides outpatient, antenatal, immunization and out-
reach services; b) Health Centre III (HC III) which serves a
sub-county and additionally provides inpatient care and
environmental health; c) Health Centre IV (HC IV) which
serves a sub-district and additionally provides surgery,
supervision of the lower HCs, data collection and health
service planning. There are also 57 government hospi-
tals, including 10 regional referral and teaching hospi-
tals. For the purposes of comparison across countries
HC IIs and national hospitals were not included and
health facilities were classified as follows: a) primary:
HC IIIs; b) secondary: HC IVs and district hospitals, as
their roles in ART provision are similar; and c) tertiary:
regional referral hospitals.
Zimbabwe (population 12.7 million) had a 2012 HIV
prevalence of 15% among those aged 15–49 [15]. At the
time of the baseline study, end 2011, 476,000 HIV-
positive individuals were alive and on treatment [33] and
ART provision was according to the 2010 WHO guide-
lines [2]. The health system in Zimbabwe is organized
very similarly to Malawi with 4 tiers: a) primary: health
clinics and rural hospitals run by primary care nurses
with no resident doctor; b) secondary: district or general
hospitals with a resident medical officer; c) tertiary: 7
provincial referral centres; and d) quaternary: 6 national
central hospitals, connected by a referral system. There
are provincial medical directorates responsible for co-
ordinating districts within each province.
Study Design
A purposeful sample of 81 health facilities were selected
in 3 regions of Malawi, 22 districts of Uganda and 4 dis-
tricts in Zimbabwe, representing different geographical
regions (Figure 1). The study sites were chosen to reflect
a mix of rural, semi-urban and urban sites at the pri-
mary, secondary and tertiary health facility level. Facil-
ities included those at different stages of ART provision
(including primary care facilities with no ART provision)
and areas at which the Lablite project [34] will be imple-
mented. The facilities were reflective of the division of
service provision in these settings between the Ministries
of Health (MoHs) and private/mission facilities with ser-
vices agreements with the public health system, as well
as the different systems of health sector decentralization.
Sites were selected with the direction of Ministries of
Health at the national and provincial/district levels. Pri-
mary care facilities had very limited or no research links
prior to Lablite.
A questionnaire (Additional file 1) was administered
by a senior member of the study research team who had
experience in conducting surveys and had a medical
background. The study respondents were the in-charge
staff of the facility, or a representative who was able to
provide details on service provision and health care pro-
vider training at the site. Using mixed methods, the
questionnaire was designed to capture information in 5
relevant areas: a) general facility description, overview of
services provided and human resources for health
(HRH) capacity, b) HIV testing and counselling (HTC)
services, c) Prevention of Mother to Child Transmission
of HIV (PMTCT) services, d) ART services, e) laboratory
services. At the first visit to the facility an appropriate re-
spondent who was fluent in English, was identified for each
section of the questionnaire based on the best facility-level
knowledge of the relevant area. No compensation was pro-
vided for participation in the study, and therefore the study
investigators scheduled their data collection around the
clinical responsibilities of the respondents. For section a)
this was the nurse-in-charge or someone who had in-depth
knowledge of human resources, inpatient and outpatient
services and the referral system at the facility and commu-
nity; for section b) this was an ART nurse/clinician/doctor;
for section c) this was a PMTCT nurse or midwife; for
section d) this was an ART nurse/clinician/doctor; and for
section e) this was a laboratory technician.
Data collection in Malawi occurred in October 2011
(Southern Region) and March 2012 (Central and North-
ern Region), in Uganda in November 2011-April 2012,
and in Zimbabwe in January-July 2012. In most facilities,
data collection took 1 day, although, in some, data collec-
tors returned for an additional day to collect information.
Questions were related to service provision at the day of
collection; information on stock-outs and numbers of
CD4 tests were collected for the 3 months (quarter) prior
to the interview date. For information regarding numbers
of clients (e.g. ART patients and numbers of visits) inter-
viewees referred to appropriate registers and records. For
information regarding stock outs of HIV test kits and
drugs, data were collected on the number of days in the
3 month period that the facility had no stock and inter-
viewees referred to pharmacy records.
Descriptive statistical analysis was conducted on the
cross-sectional data stratifying findings by health care
system level using the definitions outlined above.
Ethics statement
The study received ethical approval from the Malawi
National Health Sciences Research Committee, the Joint
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Figure 1 Country Maps Demonstrating Geographic Locations of Cross Sectional Survey. A. Locations of Malawi, Uganda and Zimbabwe in
sub-Saharan Africa. B. Uganda: Dots indicate 22 districts included in the survey. 13 health facilities from 4 districts in the Central Region, 14 health
facilities from 6 districts in the Northern Region, 6 health facilities from 6 districts in the Eastern Region and 6 health facilities from 6 districts in
the Western Region were surveyed. Implementation project is taking place in Kalungu (Central Region) and Agago (Northern Region). C. Zimbabwe: 5
health facilities from Zvimba District (site of implementation project), 6 health facilities from Chikomba District, 3 health facilities from
Shamva District, 6 health facilities from Makoni District and 2 health facilities in Harare were surveyed. D. Malawi: 3 health facilities from
Chitipa (Northern Region), 3 health facilities from Lilongwe (Central Region) and 15 health facilities from Phalombe (Southern Region and
site of implementation project) were surveyed.
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Clinical Research Centre-Uganda Institutional Review
Board/Research Ethics Committee, the Uganda National
Council of Science and Technology, and the Medical Re-
search Council of Zimbabwe. Informed written consent
was obtained from the health care workers who com-
pleted the survey. The consent procedure was approved
by the reviewing ethics committees/research boards and
forms were translated into the local language as well as
English. No individual-level patient data were collected.
Results
Characteristics of all health facilities included in the
Lablite cross-sectional baseline survey
Description of health systems organization of all
health facilities
In total, 53 primary care facilities (16 in Malawi, 21 in
Uganda and 16 in Zimbabwe) and 25 secondary care fa-
cilities [3 in Malawi, 16 in Uganda (8 HC IVs and 8 dis-
trict hospitals), 6 in Zimbabwe] were included. Tertiary
referral centres at Kamuzu Central Hospital in Malawi
and Kabale and Gulu Regional Referral Hospitals in
Uganda were surveyed; no tertiary level site was sur-
veyed in Zimbabwe (Table 1).
For non-ART related outpatient consultations, public
sector facilities run by MoH did not charge users fees in
Malawi, however all mission facilities run by the Christian
Health Association of Malawi (CHAM) did (5/20). In
Uganda only 5/39 facilities charged for outpatient consul-
tations (2 public sector, 2 Christian Health Association
and 1 mission-run facility), all in secondary care. Con-
versely, in Zimbabwe, only 4/22 facilities did not charge
users fees for outpatients, all in primary care (3 public sec-
tor and 1 Catholic mission).
The majority of primary care facilities were rural and
in Malawi and Uganda, most were served by dirt road as
opposed to all-weather tarmac roads. Secondary care fa-
cilities included a mixture of rural, peri-urban and urban
facilities. All tertiary centres were urban. Median (range)
reported time to travel to the nearest tertiary level facil-
ity by vehicle from primary and secondary level referring
facilities was 1.8 hours (0.25-6) in Malawi and 1.5 hours
(0.25-3.5) in Zimbabwe (data not available in Uganda).
The catchment population of these facilities had wide
variation, between and within country; primary care fa-
cilities on average served larger catchment populations
in Malawi than in Uganda or Zimbabwe and urban pri-
mary care facilities were more likely to serve larger pop-
ulations than rural or peri-urban centres.
Staffing at primary level facilities was predominantly
comprised of nurses/midwives, although all but one facil-
ity in Malawi and Uganda were led by a non-physician
clinical officer/medical assistant. Of note, in Malawi where
there has been formalization of a community health
worker cadre, known as the health surveillance assistant
(HSA), 57% of non-administrative clinic staff in primary
care were HSAs compared to 2% in Uganda and 12% in
Zimbabwe, with most facilities in Uganda and Zimbabwe
having no health care workers of this cadre. Only 6/16,
14/21 and 1/16 primary care facilities in Malawi, Uganda
and Zimbabwe respectively had a laboratory technician or
assistant, whereas most higher level facilities had several
laboratory staff. Low numbers of administrative staff at the
primary care level means administrative tasks fall to the
frontline clinical staff; in Malawi, Uganda and Zimbabwe,
7/16 and 6/21 and 3/16 primary care sites had administra-
tive staff. There were more administrative staff in second-
ary and tertiary level facilities.
Availability of clinical and laboratory services at all health
facilities
Primary care facilities in all three countries offered basic
care to patients including outpatient adult and paediatric
medical care, family planning, antenatal care, and labour
and delivery services (Table 2). All offered HTC and the
majority provided PMTCT and cotrimoxazole preventive
therapy (CPT) for HIV-positive patients. Most provided
on-going TB treatment although in Malawi initiation of
TB treatment may be in secondary care. They provided
referrals for TB care to higher level health facilities as
appropriate. Isoniazid preventive therapy (IPT) for
HIV-positive patients was implemented at 38%, 29%
and 6% of all primary facilities in Malawi, Uganda and
Zimbabwe, respectively.
At the time of the survey, decentralization of ART
was incomplete: 9/16 primary care facilities in Malawi,
6/21 in Uganda and 15/16 in Zimbabwe had on-site
ART provision. In all but one facility in Zimbabwe ART
provision at the primary health level was conducted by
mobile outreach teams from referral centres, as opposed
to existing health facility staff. All secondary and tertiary
care facilities provided ART. Early infant diagnosis
through dry blood spots (DBS) DNA-PCR programming
was reported as accessible offsite by referral in 9/11 (5
sites missing data), 14/21 and 13/13 (3 sites missing data)
primary care sites in Malawi, Uganda and Zimbabwe
respectively.
Simple on-site laboratory tests (Table 2) were more
likely to be provided at the primary level in Uganda
[haemoglobin 9/21 (43%) facilities; malaria testing 16/21
(76%); sputum microscopy for TB 15/21 (71%)] than in
Malawi [6/16 (38%); 8/16 (50%); 6/16 (38%)] or
Zimbabwe [2/16 (13%), 13/16 (81%), 1/16 (6%)]. One sec-
ondary care facility in Malawi did not have TB sputum mi-
croscopy and one secondary care site in Zimbabwe did
not measure haemoglobin on-site, otherwise these tests
were available in secondary and tertiary care. Cryptococcal
diagnosis (antigen testing or India ink) was seldom avail-
able in primary care [0/16 (0%), 2/21 (10%) and 1/16 (6%)
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Table 1 General characteristics and staffing in all health facilities included in the baseline survey
Malawi Uganda Zimbabwe
Primary (n = 16) Secondary (n = 3) Tertiary (n = 1) Primary (n = 21) Secondary (n = 16) Tertiary (n = 2) Primary (n = 16) Secondary (n = 6)
Owner
Public/MoH1 12 (75) 2 (66) 1 (100) 20 (95) 12 (75) 2 (100) 12 (75) 5 (83)
Private not for profit2 4 (25) 1 (33) 0 (0) 1 (5) 4 (25) 0 (0) 4 (25) 1 (17)
Charges for out-patient consultations
No 12 (75) 2 (66) 1 (100) 21 (100) 11 (69) 2 (100) 4 (25) 0 (0)
Yes 4 (25) 1 (33) 0 (0) 0 (0) 5 (31) 0 (0) 12 (75) 6 (100)
Location
Urban 2 (13) 1 (33) 1 (100) 3 (14) 4 (25) 2 (100) 2 (13) 1 (17)
Peri-urban 3 (19) 1 (33) 0 (0) 3 (14) 6 (38) 0 (0) 1 (6) 0 (0)
Rural 11 (69) 1 (33) 0 (0) 15 (71) 6 (38) 0 (0) 13 (81) 5 (83)
Access road
Tarmac 3 (19) 1 (33) 1 (100) 1 (5) 6 (38) 1 (50) 12 (75) 6 (100)
Functioning dirt road 13 (81) 2 (66) 0 (0) 20 (95) 9 (56) 1 (50) 4 (25) 0 (0)
Water transport 0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 0 (0) 0 (0) 0 (0)
Catchment population:
Median (range)
29,275 (11,074-
240,000)
50,015 (29,721-
1,897,168)
5,490,000 9,000 (325–
210,000)
70,295 (2,400-
500,000)
2,250,000 (1,500,000-
3,000,000)
8,616 (3,122-
113,000)
13,747 (9,184-
298,495)
Time (hours) to nearest tertiary
facility: Median (range)
1.9 (.33-6) 1.5 (.25-5) - 1.5 (.33-3.5) 1.3 (.25-2)
Physicians 0 (0–0) 2.8 (1.5-4) 0 (0–0) 2 (1–4.5) 5.5 (5–6) 0 (0–0) 1 (1–1)
Clinical Officers/Medical Assistants 1 (1–2) 25 (11–40) 2 (1–2) 4.5 (2–8) 19 (8–29) 0 (0–0) 1 (0–1)
Midwives/Nurses 2.5 (1–4.5) 42 (34–49) 309 4 (3–6) 22 (13–68) 99 (59–138) 6 (2.5-14) 66 (46–82)
Counsellors 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–1) 0 (0–0) 1 (1–1) 4 (3–4)
Laboratory technicians/assistants3 0 (0–0.5) 4.5 (3–6) 1 (0–1) 2 (1.8-3) 8.5 (8–9) 0 (0–0) 3 (2–4)
Auxiliary staff4 5 (3.5-7.5) 70 (40–101) 2 (0–3) 6 (0–8) 57 (13–100) 3 (3–9) 64 (52–93)
Community health workers 18 (11–22) 31 (21–40) 0 (0–0) 0 (0–3) 2 (0–4) 0 (0-.5) 0 (0–0)
Administrative staff 0 (0–2) 7 (3–11) 0 (0–1) 1 (.5-6) 10 (7–13) 0 (0–0) 13 (6–18)
Values are n (col%) or median (IQR) unless stated otherwise. Where numbers do not sum to total this is missing data; additional missing data were as follows: catchment population (1 primary facility Malawi), time to
nearest tertiary facility (3 primary facilities Zimbabwe; not collected in Uganda), staffing data (one secondary facility in Malawi only had data on numbers of physicians, one secondary care facility in Malawi had no
data on number of physicians; tertiary care facility in Malawi only had data on number of midwives/nurses).
1Ministry of Health, local government or Rural District Council (Zimbabwe).
2Christian health association, Catholic mission, other mission or City of Harare (Zimbabwe).
3Laboratory staff were laboratory technicians except in Malawi, where in primary facilities there were 6 laboratory technicians and 2 laboratory assistants and in Uganda where in primary facilities there were 15
laboratory technicians and 2 laboratory assistants, in secondary facilities there were 29 laboratory technicians, 3 laboratory assistants, 1 microscopist and 11 unspecified laboratory staff, and in tertiary facilities there
were 12 laboratory technicians and 5 laboratory assistants.
4Auxiliary staff include pharmacy, radiology staff as follows: Malawi: primary: 2 pharmacy technicians; secondary: 2 pharmacy technicians, 2 radiology staff; Uganda: primary: 0; secondary: 1 pharmacist, 2 pharmacy
assistants, 2 radiographers; tertiary: 2 pharmacy technicians, 2 radiographers; Zimbabwe: primary: 0; secondary: 2 pharmacists, 4 pharmacy technicians, 1 radiographer, 1 x-ray operator.
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facilities in Malawi, Uganda and Zimbabwe] but mostly
available in secondary care (all facilities in Malawi and
Zimbabwe and 11/16 (69%) facilities in Uganda) and al-
ways in tertiary care. Microbiology (blood culture) was not
readily available other than at 1 secondary and 1 tertiary re-
ferral hospital in Malawi (both through an academic re-
search partnership), 1 secondary referral hospital in Uganda
and 3 secondary level facilities in Zimbabwe. Only one pri-
mary care facility provided chest radiography on-site (in
Malawi). In secondary care, chest radiography was available
in 3/3 (100%), 9/16 (56%) and 4/6 (67%) facilities in Malawi,
Uganda and Zimbabwe. The three tertiary care sites pro-
vided chest radiography.
Availability of key commodities for routine HIV care in all
health facilities
Table 3 outlines stock outs of key commodities in HIV
care in all facilities. Across the items surveyed, ART drugs
for adults were largely available most of the time at all
levels. Stock-outs of paediatric ART were problematic in
Uganda where 3 of the 6 primary care facilities with ART
provision and 3/16 secondary care facilities reported a
stock-out in the three months prior to survey. Uganda re-
corded stock-outs at all levels for TB drugs, antibiotics
and HIV commodities. Drug stock levels for opportunistic
infections or management of intercurrent illness were not
assessed, beyond antibiotics.
Stock outs of HIV test kits were noted in all three
countries and, in Uganda, across all levels of care. Re-
cent stock-outs of HIV-testing kits were not only fre-
quent (Malawi: 55%, Uganda: 26%, Zimbabwe: 9% across
all facility levels), but they often lasted for long periods
of time (median days out of stock over 3 months were
16, 18 and 6 in Malawi, Uganda and Zimbabwe respect-
ively). Similarly, although cotrimoxazole prophylaxis for
HIV-positive patients was provided in 80/81 facilities,
stock-outs occurred in 58%, 32%, and 9% of all facilities
in Malawi, Uganda and Zimbabwe respectively.
Characteristics of health facilities with on-site ART
provision available
ART service availability and utilization at health facilities
Decentralization of ART has been rolled out to the pri-
mary health facility level since 2005 in all three countries
Table 2 Provision of services on-site in all health facilities included in the baseline survey
Malawi Uganda Zimbabwe
Primary
(n = 16)
Secondary
(n = 3)
Tertiary
(n = 1)
Primary
(n = 21)
Secondary
(n = 16)
Tertiary
(n = 2)
Primary
(n = 16)
Secondary
(n = 6)
Clinical services
Adult medical care 16 (100) 3 (100) 1 (100) 21 (100) 16 (100) 2 (100) 15 (94) 6 (100)
Paediatric medical care 16 (100) 3 (100) 1 (100) 20 (95) 16 (100) 2 (100) 14 (88) 6 (100)
Antenatal care 15 (94) 3 (100) 1 (100) 21 (100) 16 (100) 2 (100) 16 (100) 6 (100)
Obstetric care 12 (75) 3 (100) 1 (100) 18 (86) 16 (100) 2 (100) 16 (100) 6 (100)
Family planning 13 (81) 2 (67) 1 (100) 21 (100) 15 (94) 2 (100) 15 (100) 5 (83)
TB treatment 16 (100) 3 (100) 1 (100) 17 (81) 16 (100) 2 (100) 14 (88) 6 (100)
HIV testing and counselling 16 (100) 3 (100) 1 (100) 21 (100) 16 (100) 2 (100) 16 (100) 6 (100)
PMTCT 15 (94) 3 (100) 1 (100) 21 (100) 16 (100) 2 (100) 16 (100) 6 (100)
DNA PCR for infant diagnosis (off site)1 9 (82) 3 (100) 1 (100) 14 (67) 13 (81) 2 (100) 13 (100) 5 (100)
Cotrimoxazole prophylaxis for HIV positive patients 15 (94) 3 (100) 1 (100) 19 (90) 16 (100) 2 (100) 16 (100) 6 (100)
Isoniazid preventative therapy
for HIV positive patients
6 (38) 1 (33) 1 (100) 6 (29) 6 (38) 2 (100) 1 (6) 3 (50)
Antiretroviral therapy 9 (56) 3 (100) 1 (100) 6 (29) 16 (100) 2 (100) 15 (94) 6 (100)
Laboratory services
Haemoglobin 6 (38) 3 (100) 1 (100) 9 (43) 16 (100) 2 (100) 2 (13) 5 (83)
Malaria diagnosis (rapid or microscopy) 8 (50) 3 (100) 1 (100) 16 (76) 16 (100) 2 (100) 13 (81) 5 (83)
Sputum microscopy for TB 6 (38) 2 (67) 1 (100) 15 (71) 16 (100) 2 (100) 1 (6) 6 (100)
CSF microscopy 0 (0) 3 (100) 1 (100) 2 (10) 10 (63) 2 (100) 1 (6) 4 (67)
Cryptococcal diagnosis (Ag or microscopy) 0 (0) 3 (100) 1 (100) 2 (10) 11 (69) 2 (100) 1 (6) 6 (100)
Blood culture 0 (0) 1 (33) 1 (100) 0 (0) 1 (6) 0 (0) 0 (0) 3 (50)
Chest x-ray 1 (6) 3 (100) 1 (100) 0 (0) 9 (56) 2 (100) 0 (0) 4 (67)
Values are n (col %).
1Missing data for some facilities means that the denominators were not 100% of facilities in all columns for infant diagnosis. Percentages are of non-missing data.
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Table 3 Stock-outs of HIV-test-kits and drugs in all health facilities over three months prior to survey
Malawi Uganda Zimbabwe
Primary Secondary Tertiary Primary Secondary Tertiary Primary Secondary
(n = 16) (n = 3) (n = 1) (n = 21) (n = 16) (n = 2) (n = 16) (n = 6)
Antibiotics
No. facilities with stock-outs 5/16 1/3 0/1 17/21 6/16 2/2 4/16 0/6
No. days/90 per facility if >0 14,14,30,60,60 30 14,14,14,21,30,30,30,30,35,42,59,60,60,60,70,75,90 7,10,14,21,28,30 14,30 5,7,90,90
TB drugs
No. facilities with stock-outs 1/16 1/3 0/1 9/17 2/16 1/2 2/14 1/6
No. days/90 per facility if >0 2 30 7,14,14,15,30,31,60,60,90 31,90 30 3,60 14
Anti-malarial drugs
No. facilities with stock-outs 2/16 0/3 0/1 3/21 2/16 0/2 1/16 0/6
No. days/90 per facility if >0 5,7 14,14,14 21,30 7
HIV test kits
No. facilities with stock-outs 10/16 1/3 0/1 5/21 4/16 1/2 2/16 0/6
No. days/90 per facility if >0 3,8,14,14,14, 18,23,25,30, 30 Days missing 3,14,30,30,30 5,7,21,90 1 4,7
Cotrimoxazole for HIV positive patients
No. facilities with stock-outs 11/15 0/3 0/1 8/19 4/16 0/2 1/16 1/6
No. days/90 per facility if >0 14,21,31,45,60,60,66,70,90,90,90 20,21,60,60,66,90,90,90 28,30,60,90 7 90
ART for PMTCT
No. facilities with stock-outs 2/15 2/3 1/1 3/21 1/16 0/2 0/16 0/6
No. days/90 per facility if >0 14,60 7,90 62 2,14,60 31
Adult ART
No. facilities with stock-outs 0/9 1/3 0/1 0/6 0/16 0/2 1/1 1/6
No. days/90 per facility if >0 30 30 14
Paediatric ART
No. facilities with stock-outs 2/9 0/3 0/1 3/6 3/16 0/2 2/6
No. days/90 per facility if >0 1,7 14,90,90 14,30,60 14,40
Where denominator for facilities with stock outs is less than total facilities it is because the facility does not provide the relevant service. Additionally, for facilities in Zimbabwe providing ART, stock-outs are only
applicable where the provision is static as opposed to outreach.
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but was only available in a subset of primary care facil-
ities in this sample (Table 4). In total, 13 facilities in
Malawi had on site ART provision including 9 primary
care facilities; corresponding numbers were 24 facilities
(including 6 primary care) in Uganda and 21 facilities
(including 15 primary care; one of the 15 did no ART initi-
ation) in Zimbabwe. In Malawi and Uganda the number of
days the ART clinic ran per week varied in both primary
and secondary care. In Zimbabwe, ART provision in pri-
mary health centres was predominantly conducted by an
outreach team visiting from a referral centre (every
2 weeks) as opposed to by existing health facility staff. In
Malawi and Uganda all facilities with ART provision were
able to initiate and follow-up children on ART; in
Zimbabwe 3/15 primary care facilities (with any ART
provision on site) did not initiate children on ART on-site
and 1/15 did no paediatric follow-up. At only 2 sites was
ART available at Maternity or ANC/PMTCT at the time
of the study.
The total patients (adults and children) on ART in a pri-
mary care facility were highest in Malawi and lower in
Uganda and Zimbabwe; as expected larger numbers were
generally treated in Health Centre Level IV facilities or
hospitals. In facilities in Uganda and Zimbabwe with adult
and paediatric patients on ART, children constituted 8%
and 8% of all individuals on ART respectively; and 11%
and 14% of new patient initiations. This compares with es-
timated proportions in need of 16% and 14% [15]. These
breakdowns were not available for Malawi.
ART drug regimen utilization: Adults, Paediatric and
PMTCT regimens
In terms of first line adult ART regimens, across all facil-
ities with ART provision in Malawi half (6/12; 1/13 pro-
vided no information) at the time of survey had Tenofovir
(TDF)-based regimens available; otherwise Stavudine
(d4T)-based regimens were still being used as the stan-
dardized first-line regimen (Additional file 2: Table S1a).
In Uganda d4T has been phased out, and sites at all levels
are giving either Zidovudine (ZDV)- or TDF-based first-
line regimens, the latter available mainly at secondary cen-
tres. In Zimbabwe, the picture was more similar to Malawi
Table 4 ART service provision and usage in health facilities providing ART on-site
Malawi Uganda Zimbabwe
Primary Secondary Tertiary Primary Secondary Tertiary Primary Secondary
(n = 9) (n = 3) (n = 1) (n = 6) (n = 16) (n = 2) (n = 151) (n = 6)
Provision start year2
2003-04 0 (0) 0 (0) 1 (100) 0 (0) 3 (20) 2 (100) 0 (0) 0 (0)
2005-06 1 (11) 1 (33) 0 (0) 2 (33) 12 (80) 0 (0) 2 (13) 3 (50)
2007-08 3 (33) 2 (66) 0 (0) 2 (33) 0 (0) 0 (0) 4 (27) 2 (33)
2009-10 2 (22) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 7 (47) 1 (17)
2011 3 (33) 0 (0) 0 (0) 1 (17) 0 (0) 0 (0) 2 (13) 0 (0)
Days service provided
1/fortnight 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 14 (93) 0 (0)
1-2/week 8 (89) 2 (66) 0 (0) 3 (50) 4 (25) 0 (0) 0 (0) 1 (17)
3-4/week 1 (11) 0 (0) 0 (0) 1 (17) 3 (19) 1 (50) 0 (0) 0 (0)
5/week 0 (0) 1 (33) 1 (100) 2 (33) 9 (56) 1 (50) 1 (7) 5 (100)
Adults ≥15
on ART3,4
516 (241–886) 2610 (2,438-9,600) 17,453 189 (56–604) 576 (385–890) 1,968 (1,523-2,412) 203 (97–359) 2,800 (1,976-3,726)
Adults ≥15
initiating ART
per month4
49 (30–55) 37 (25–478) 597 11 (7–19) 25 (12–34) 66 (35–97) 13 (6–20) 50 (40–100)
Children on ART3,4 22 (9–51) 44 (21–59) 230 (223–237) 19 (10–31) 203 (165–318)
Children initiating
ART per month4
4 (1–7) 7 (5–23) 27 1.5 (1–5) 3 (2–5) 3.5 (2–5) 2.5 (1–4.5) 5 (3–10)
Values are n (col%) or median (IQR).
1One primary care facility in Zimbabwe had a static ART clinic but did no ART initiation for children < 10 (numbers of children initiating and followed up not
included); 14 primary care facilities provided outreach clinics. 13/14 primary care facilities with outreach initiated adults on ART; 12/14 initiated children. 14/14
followed up adults, 13/14 followed up children.
2Where numbers do not sum to column total this is due to missing data, percentages are presented for non-missing data.
3Numbers on ART for Malawi are for adults and children combined (given in adults’ row). Numbers on ART missing for one primary care facility in Malawi.
4Malawian MoH data for quarter July-September 2011 were used for numbers on ART and for numbers initiating ART for 6 Phalombe facilities. Interview data were
used for facilities outside Phalombe. Zimbabwean MOH data for July-September 2011 were used for numbers on ART and numbers initiating ART (except for one
primary care facility where data used were for March-May 2012). Ugandan MoH data for quarter October-December 2011 were used for numbers on ART and
numbers initiating ART (except for 3 primary care sites and 2 secondary care sites where interview data were used for numbers initiating).
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and both countries had ZDV-based ‘alternative’ first-line
regimens available at about one third of facilities. Boosted-
Lopinavir (LPV/r) was the second-line regimen available
in all countries; one Ugandan tertiary site also had
boosted-Atazanavir (ATV/r). Few primary health facilities
had second line available on-site, whereas 3/4, 15/18, and
4/6 secondary and tertiary level facilities had second line
drugs available on-site in Malawi, Uganda and Zimbabwe
respectively (Additional file 2: Table S1a).
ZDV-based regimens were primarily used for first-line
ART for children in Malawi at sites at all levels (10/13)
and Uganda (21/24). In Zimbabwe, d4T-regimens were
being used in primary care facilities but secondary facil-
ities had changed to ZDV. First-line regimens including
Abacavir (ABC) were only used in Uganda (5 secondary/
tertiary facilities). TDF was available for children in 3 facil-
ities in Uganda, presumably in adolescents. LPV/r was
very rarely used as first-line for young children (only 2 fa-
cilities in Uganda; 1 facility in Zimbabwe). Where avail-
able, second-line ART was almost always LPV/r and the
pattern of referral was similar to adults. In many sites it
appeared that children were receiving adult as opposed
to specific paediatric formulations (Additional file 2:
Table S1b).
For PMTCT drug regimens, in Malawi TDF-based ART
was available in 63% facilities, in tandem with the planned
roll-out of the Option B + PMTCT strategy, with the re-
mainder doing Option A. Most (75%) facilities reported
using infant nevirapine (NVP), including those where TDF-
based ART was being used. In Uganda and Zimbabwe,
Option A was being used almost universally, with infants
receiving liquid NVP prophylaxis during the period of risk
(Additional file 2: Table S1c).
Availability of laboratory services for monitoring treatment
toxicity at health facilities with on-site ART provision
Primary and secondary level sites with ART provision
were extremely limited with respect to on-site ability to
provide laboratory testing for monitoring of side effects
and treatment failure, in particular at the primary health
care level (Figure 2). Haemoglobin was available on-site at
5/9, 5/6 and 2/15 primary care facilities, by up-referral in a
further 1/9, 1/6 and 8/15 facilities in Malawi, Uganda and
Zimbabwe respectively and not at all in the remainder.
One secondary care facility in Zimbabwe did not provide
haemoglobin but other secondary and all tertiary level fa-
cilities did so. White blood cells counts were only available
on site in 2 primary care facilities (1 in Malawi and 1 in
Uganda) and by referral in 2/9, 2/6 and 9/15 facilities.
Most secondary care (2/3, 13/16 and 5/6) and all tertiary
care facilities had on-site testing of full blood counts. In
terms of basic biochemistry, liver function tests were less
available and in primary care only 1/9, 2/6 and 8/15 facil-
ities respectively could refer for tests (no on-site testing);
numbers in secondary care were 1/3 (on-site), 12/16
(5 on-site) and 5/6 (4 on-site); 2/3 tertiary facilities had
on-site testing (1 off site in Uganda). Access to urea and
creatinine was similar.
Availability and utilization of CD4 and viral load testing for
monitoring treatment effectiveness in health facilities
providing ART
CD4 testing was available on-site at 2 primary care facil-
ities (both in Malawi); other facilities collected samples
on-site and transported them to reference laboratories
(0/9 facilities in Malawi, 6/6 in Uganda, 13/15 in
Zimbabwe), referred patients (2/9, 0/6, 1/15) or had no
access to CD4s (5/9, 0/6, 1/15). Most secondary level fa-
cilities either had on-site CD4 testing (1/3, 7/16, 6/6) or
collected samples on-site (0/3, 8/16, 0/6). The three ter-
tiary level facilities all had on-site CD4 testing. CD4 test-
ing prior to ART initiation was used in most secondary
facilities, at least in selected patients, and, at primary
level in 4/9 facilities in Malawi, 5/6 in Uganda and in
13/14 in Zimbabwe (1/15 primary care sites in
Zimbabwe did follow-up post ART initiation only). In
Malawi CD4-monitoring on ART was not used routinely
in practice (as per national guidelines) [4], whereas in
Uganda and Zimbabwe interviewees involved in ART
provision in 5/6 and 10/14 primary care facilities re-
spectively stated that the policy was to undertake 6-
monthly CD4-monitoring on ART (missing data for one
site in Zimbabwe); corresponding numbers for higher
level facilities were 14/18 (including one facility with 3-
monthly monitoring) and 2/6 (Table 5).
Data were available on numbers of CD4 tests provided
(on or off site) over a 3-month period for 4 facilities pro-
viding ART (across all facility levels) in Malawi, 19 facilities
in Uganda and 13 facilities in Zimbabwe (Table 6). On aver-
age the number of CD4 tests conducted per month was
low given numbers of adults on ARTand numbers of adults
initiating ART. In Ugandan facilities where new patients
initiating per month had stabilised to <5% adults on ART
(so most CD4s would be used for monitoring) the ratio of
numbers of CD4 tests to adults on ART translate into an
estimated 4/12 facilities doing sufficient CD4s for 6-
monthly monitoring of adults on ART, 3/12 for annual
monitoring, 2/12 for 2-yearly monitoring and 3/12 for
less frequent monitoring. Corresponding estimates for
Zimbabwe were 0/9, 1/9, 2/9, and 6/9 (Table 6 and
Additional file 2: Table S2).
Only 2/13 (1 on-site), 3/24 (1 on-site) and 1/21 (off-
site) facilities across all facility levels in Malawi, Uganda
and Zimbabwe respectively had regular access to viral
load testing and all testing was in selected patients, not-
ably patients with signs of treatment failure (CD4 or
weight loss) or patients with TB (Figure 2 and Table 5).
Only one tertiary care facility in Malawi ever referred for
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resistance testing and it was to an academic research fa-
cility and not in the public sector.
Discussion
The Lablite project teams, working with MoHs in
Malawi, Uganda and Zimbabwe, conducted a compara-
tive cross-sectional survey of HIV service provision in a
sample of health facilities. This survey, carried out at the
start of the Lablite Project during 2012, gives an over-
view of the operational realities for patients and frontline
health workers at the facility level during a period where
countries were in various stages of transitioning [2,3,31]
from previous guidelines for ART provision to the
WHO 2010 update [35].
In this multi-country survey, HIV services were available
comprehensively within referral facilities. Primary health
facility coverage of HTC and basic PMTCT services was
also comprehensive, although stock-outs of HIV test-kits,
and drugs would clearly have limited the services at times.
Nevertheless, the findings show that coverage of ART and
paediatric HIV services (in particular) to the decentralized
health facility level remained incomplete even though roll-
out to lower level primary health care facilities of ART
had already been underway. At the time of the study,
integration of ART services into ANC or Maternity was
also not documented at any site.
The 2013 WHO Guidelines [22] advocating for adop-
tion of Option B+ [36,37] in many low resource, high
prevalence operational settings necessitates that ART
services become available and integrated into primary
health centres where there are ANC and MCH services
provided [38]. Early programmatic data shows consider-
able variation in retention on ART in Option B + women
between health facilities [39,40] as well as association of
attrition with different approaches for timing of ART initi-
ation relative to knowledge of HIV test result, place of
ART initiation (antenatal or ART clinic), place of follow-
up postnatally and post-breastfeeding, and type of support
women receive [41]. As numbers of people on therapy are
increasing, many health systems bottlenecks remain, in
particular around inadequate support of human resources
for health capacity, supply chain management and labora-
tory services infrastructure.
From a human resources perspective, successful ART
roll-out relies on task shifting of clinical services in pri-
mary care facilities [42-45]. This study highlights further
constraints beyond clinical tasks around laboratory tech-
nical capacity as well as administrative tasks. Malawi,
which has one of the lowest professional health cadres-to-
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Figure 2 Laboratory provision in health facilities providing ART on-site. Proportion of facilities with on-site provision or able to refer for
testing (remaining facilities have no provision). Referrals may be sample collection on-site with the sample sent to a reference laboratory or the
patient may be referred to an alternative facility. A. Haemoglobin. B. White cell count. C. Liver enzymes. D. Urea and creatinine. E. CD4s. F. Viral
loads. *Health facilities were asked whether or not they had regular access to CD4 and viral load testing: 1 additional facility in Malawi reported
being able to refer for CD4; 3 , 15 and 1 additional facilities in Malawi, Uganda and Zimbabwe respectively reported they could refer for viral load
testing but none did so regularly.
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population ratios in the world, has uniquely adopted miti-
gation strategies which include the utilization of a formal-
ized community health worker cadre, and use of NGO
partners to implement a standardized supportive supervi-
sion and mentorship program led by the MoH national
program.
Despite maturity of national ART roll-out programs
with many programs operating for nearly a decade or
longer, stock-outs of HIV test kits and drugs remains a
critical bottleneck to access [46,47], and needs urgent at-
tention in the light of wider access being strived for in
the WHO 2013 guidelines update. Mechanisms to fore-
cast drugs through quantification of retention in care is
particularly challenging for alternative first line and sec-
ond line regimens [48,49]. The data from this study
highlighted that even at the primary care level, due to
policy transition (e.g. d4T phase-out, introduction of
TDF, and moving from NVP to efavirenz (EFV), various
first-line regimens were available. The complexity of
movement of large quantities of people in and out of
regimen categories can be problematic during the period
of transition, as the number of regimens used becomes
more complicated with the evolution of the WHO
guidelines. Accurate forecasting and ensuring availability
of drugs is of key importance as patients may be triaged
and delayed from substituting treatment regimens due to
stock-out threats. Patients who may meet clinical criteria
to be on certain regimens may be triaged out based on
need and limited quantities. Downstream, ‘on the ground’
decisions made due to limited resources will misclassify
groups of people, and contribute to lack of sensitivity in
traditional methods of forecasting (which are based on
monitoring numbers of people retained on specific regi-
mens at a cross sectional point in time).
In our study, frequent stock outs of drugs, particularly
cotrimoxazole, were reported in Malawi and Uganda, al-
though less so in Zimbabwe. Stock outs emphasize the
need to prioritize development of stock management cap-
acities centrally and at the frontlines of delivery. Planners
need to acknowledge and respond to the potential impacts
of expanding ART eligibility criteria without adequate re-
sourcing for drugs.
Maintaining supply of HIV test kits seems to be par-
ticularly problematic [50]. Already prioritization and
quantification can be affected by challenges in coordinat-
ing multipronged HTC strategies supporting both com-
munity based screening of asymptomatic individuals, and
facility based testing through PITC. Expanded eligibility,
Table 5 Reported use of CD4 and viral load testing in health facilities providing ART on-site
Malawi Uganda Zimbabwe
Primary Secondary Tertiary Primary Secondary Tertiary Primary Secondary
(n = 9) (n = 3) (n = 1) (n = 6) (n = 16) (n = 2) (n = 15) (n = 6)
CD4 testing regularly used prior to initiation
In all patients 0 1 1 1 4 0 9 2
Selected patients1 4 2 0 4 11 2 4 3
Not used regularly 5 0 0 1 1 0 1 0
CD4 monitoring on ART in adults
Every 3 months 0 0 0 0 1 0 0 0
Every 6 months 0 0 0 5 11 2 10 2
Every 12 months 0 0 0 1 1 0 1 0
If clinically indicated 3 1 0 0 2 0 1 1
Not used regularly 6 2 1 0 1 0 2 1
CD4 monitoring on ART in children
Every 3 months 0 0 0 0 1 0 0 0
Every 6 months 0 0 0 4 11 1 9 3
Every 12 months 0 0 0 1 0 1 0 0
If clinically indicated 3 1 0 0 2 0 1 1
Not used regularly 6 2 1 0 1 0 2 1
Viral load monitoring on ART
If clinically indicated 1 0 1 0 1 2 1 0
Not used regularly 8 3 0 6 15 0 14 6
One primary care facility in Zimbabwe did no ART initiation. Two primary care facilities in Zimbabwe did not follow-up children. Otherwise, where numbers do not
sum to total this is due to missing information.
1Four facilities in Uganda included as using CD4 testing prior to initiation in selected patients were doing CD4 testing in all adults but not in all children.
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without concomitant supply side support for HTC kit
logistics may contribute to ongoing stock out issues for
facility based PITC programs targeting the patients
who are most likely to need it the most e.g. patients with
severe immunodeficiency, TB/HIV patients, HIV+ pregnant
women eligible for Option B or Option B+ strategies.
As with other literature [51], our study reinforces that
laboratory testing for drug toxicity and treatment effect-
iveness monitoring is available in these African coun-
tries, but generally not by patients accessing care at
lowest level health facilities. Even haemoglobin (a very
basic laboratory test) was available in less than half of
primary health facilities. With respect to treatment mon-
itoring, fewer lower level facilities had CD4 testing on-
site, and in Malawi, few facilities used CD4 to monitor
HIV patients (recommended for pre-ART [4]). On aver-
age the number of CD4 tests conducted per month was
lower than reported or recommended in National guide-
lines, given numbers of adults on and initiating ART,
even in sites which had access to CD4 testing. Overall
and particularly in Malawi and Zimbabwe, very few facil-
ities had any access to viral load monitoring, which is
highlighted as the preferred monitoring method in
WHO 2013 guidelines. Very few facilities have been able
to adopt the recommendations for use of viral load
monitoring for treatment failure, suggesting that in the
immediate future, reinforcement of good clinical decision-
making seems to be the most practical approach for moni-
toring patients on ART.
Finally, it is clear that paediatric HIV services are lagging
behind management of adults on ART, and our study re-
flects the low coverage of paediatric ART for those in need
in sub-Saharan Africa. Roll-out of DBS-PCR, which is im-
portant for early infant diagnosis and treatment has only
been modestly successful [52-55] despite the availability of
this modality in many countries for the last 5 years. The
availability of paediatric ART is also inconsistent, as we
show that in Uganda, stock outs of paediatric medications
are relatively common and occur more frequently than
adult ART. The paucity of child-friendly formulations [56]
in most national program supply chains should be ac-
knowledged and calls for better harmonisation across
adult and paediatric formulations. The current implemen-
tation of more aggressive PMTCT strategies should cer-
tainly lead to a decrease in paediatric HIV incidence, but
until issues of infrastructure, health care worker capacity,
and supply chain constraints are managed, gaps in paedi-
atric HIV services will remain. Acceleration of ART roll-
out to children is key and can be done without routine
toxicity monitoring [18].
One limitation of this study is that the numbers were
relatively small, but purposeful sampling allowed selec-
tion from different regions and levels of health care to
allow us to capture within country and between country
differences. An additional limitation is that sampling
may not necessarily be generalizable as representation of
each country was based on sites selected by the country
MoH partners. In Uganda, health centre IIIs and health
Table 6 CD4 tests performed per month in health facilities providing ART on-site with data available
Malawi Uganda Zimbabwe
Primary Secondary Tertiary Primary Secondary Tertiary Primary Secondary
All facilities (n = 2) (n = 1) (n = 1) (n = 4) (n = 14$) (n = 1) (n = 7) (n = 6)
CD4s per month 84 (77–91) 57 831 40 (27–141) 82 (19–152) 388 10 (6–30) 171 (12–312)
Adults* on ART 201; missing 9,600 17,453 189 (74–705) 576 (336–874) 2,412 263 (129–1,845) 2,800 (1,976-3,726)
Adults initiating
ART per month
46 (40–52) 478 597 11 (7–22) 27 (12–34) 35 13 (6–20) 50 (40–100)
Facilities where adults initiating
ART per month <5% total
adults* on ART
(n = 0) (n = 1) (n = 1) (n = 2) (n = 9$$) (n = 1) (n = 4) (n = 5)
Estimated frequency of
CD4s in adults* on ART**
At least 6-monthly 0 0 2 2 0 0 0
Every 6 months to 1 year 0 0 0 2 1 0 1
Every 1 to 2 years 0 1 0 2 0 1 1
Less than once every 2 years 1 0 0 3 0 3 3
Values are median (IQR) or n.
Sample collection and testing was on-site at all facilities in Malawi, tertiary care facilities in Uganda and secondary care facilities in Zimbabwe. Samples were taken
on-site and sent to a referral laboratory at all primary care facilities in Uganda and Zimbabwe.
$Sample collection and testing on-site (n = 7), samples taken on-site and sent to a referral laboratory (n = 6), patients sent to a referral laboratory (n = 1).
$$Sample collection and testing on-site (n = 4), samples taken on-site and sent to a referral laboratory (n = 4), patients sent to a referral laboratory (n = 1).
*Current adult patients at facility (except for Malawi where numbers are all ART patients).
**Estimated assuming constant number of patients on ART and constant rate of CD4-testing (includes all CD4s although some will be for initiation or in children).
Of these facilities 0/1, 0/1 facilities in Malawi, 2/2, 6/9, 1/1 facilities in Uganda and 2/4, 2/5 facilities in Zimbabwe reported CD4-monitoring in adults was at least
6-monthly (across non-empty cells).
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centre IVs were selected from all four regions of the
country, thus results are most generalizable nationally.
In Zimbabwe facilities were included in 1 district each
of 4 provinces (all in the North-East), namely,
Mashonaland East, West, Central and Manicaland. Two
urban facilities in the capital city were included for
comparison. In Malawi, 3 facilities in the Northern re-
gion (2 rural, 1 periurban referral hospital in Chitipa
District), 3 facilities in the Central region (1 urban ter-
tiary hospital, 2 periurban facilities in Lilongwe District)
and all 14 health facilities in the Phalombe District
Health Office in the Southern Region (1 referral hos-
pital, and a mixture of mission and public primary
health facilities) were selected thus some inter-regional
variations may have been missed. Data collected applied
to the day of interview or, for stock-outs of HIV test kits
and drugs, to the 3 months prior to the interview.
Whereas the most recent data may be most reliable, this
approach cannot capture trends, seasonal variations or
unusual fluctuations. However, overall this survey is
likely to provide a reasonable snapshot of health facil-
ities by country and by level at one point in time. Most
data were collected by interview and it is possible that
the interviewees provided answers with a social desir-
ability bias, in the belief that funding might be forth-
coming if they highlighted the shortages and needs in
services. A final limitation is that some data were ex-
tracted from the existing MoH monitoring and evalu-
ation tools for HIV, and there may be some concerns
regarding accuracy and consistency of such operational
data. In Malawi, where facility level is available electron-
ically through the national M and E system, data was
harmonized with the national data to confirm accuracy
and generalizability.
In the context of the recent release of the 2013 WHO
guidelines [22], we can anticipate that the variability in
practice and challenges on the ground documented in
this study, can be expected to continue to be implemen-
tation bottlenecks to operationalizing expanded eligibil-
ity criteria. Care should be taken to quantify economic
and operational feasibility especially in high prevalence,
resource-limited countries where the approach to treat-
ment is standardized and not individualized by clini-
cians. This survey was undertaken before roll-out of the
Option B-plus strategy and we plan to repeat it in 2014.
As Malawi and Uganda have since started Option B-plus
and Zimbabwe is planning to start shortly, we will have
the opportunity to compare the effect on ART roll-out
before and after adoption of Option B-plus, as well as
across the three countries.
Conclusions
At the time of this survey, provision of HTC and PMTCT
services was comprehensive across facility levels in Malawi,
Uganda and Zimbabwe, although limited by stock-outs of
supplies at some facilities. Decentralization of ART to pri-
mary care was ongoing but incomplete, being furthest
ahead in Malawi; in Zimbabwe, ART provision in primary
care was mostly by outreach teams, and in Uganda,
provision was limited at primary care level. We found clear
evidence of task shifting of clinic services in Malawi, but la-
boratory services were very limited in primary care, reinfor-
cing the importance of good clinical management of
patients. Stock-outs of drugs, particularly cotrimoxazole,
and HIV-test kits, were reported in a number of facilities
particularly in Uganda and Malawi. As demand for ART in-
creases with adoption of Option B + (lifelong ART for preg-
nant and breastfeeding HIV-positive women) and higher
threshold for ART initiation in the WHO 2013 guidelines,
challenges of service provision on the ground may well in-
crease if the health service barriers identified in this survey
are not addressed concurrently.
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